Welcome to our dedicated page for Adtalem Global Ed SEC filings (Ticker: ATGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Adtalem Global Education Inc. (NYSE: ATGE), a for-profit operator of colleges, universities, and professional schools with a strong emphasis on healthcare education. As a New York Stock Exchange–listed company, Adtalem files periodic and current reports that offer detailed information on its operations, financial condition, governance, and shareholder-related actions.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain segment-level data for the Chamberlain, Walden, and Medical and Veterinary segments, along with discussions of enrollment, revenue, operating income, and risk factors. These filings help readers understand how institutions such as Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine contribute to Adtalem’s overall results.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered the announcement of a new share repurchase authorization of up to $750 million and the completion of a prior $150 million repurchase program, the release of quarterly financial results, the retirement of the president of Chamberlain University, and the adoption of a Rule 10b5-1 trading plan by the company’s chief executive officer. Another 8-K reports the results of Adtalem’s annual meeting of shareholders, including director elections, auditor ratification, and an advisory vote on executive compensation.
Investors can also review Forms 4 and related insider trading disclosures referenced in company communications, which report transactions executed under trading plans such as the disclosed Rule 10b5-1 plan. Together, these filings provide a regulatory record of Adtalem’s financial performance, capital allocation decisions, governance matters, and insider activity.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy documents, making it easier to identify segment performance, capital allocation actions, and governance changes without reading every page. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, and Form 4 filings for ATGE are available promptly, while AI-generated explanations help readers interpret complex disclosures in accessible language.
Covista Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 1,751,336 shares of Common Stock, representing 5.07% of the class as of 03/31/2026. The filer reports sole dispositive power over 1,751,336 shares and sole voting power over 260,800 shares. The filing states the ownership reflects holdings across Vanguard Capital Management LLC and certain affiliates and includes shares held by managed funds and client accounts. The filing was signed on 04/29/2026.
Covista Inc reports that Vanguard Portfolio Management holds 2,451,249 shares of Common Stock, representing 7.1% of the class. The filing shows Vanguard has sole dispositive power over 2,451,249 shares and sole voting power over 29,643 shares. The disclosure identifies the reporting chain of Vanguard Portfolio Management LLC and affiliated voting/dispositive arrangements.
Covista Inc. executive Liles Scott, President, Medical and Vet, used company shares to cover taxes on vested equity. On April 15, 2026, 448 shares of Common Stock were withheld at $112.49 per share to satisfy tax obligations tied to previously awarded restricted stock units. After this non-market, tax-withholding disposition, Scott directly holds 13,103 shares of Covista common stock.
Dimensional Fund Advisors LP reports ownership of 1,773,564 shares of Covista Inc common stock, representing 5.1% of the class as of 03/31/2026. The filing states the shares are owned by Dimensional-managed funds and that Dimensional disclaims beneficial ownership; Sole voting power is reported as 1,730,764 and sole dispositive power as 1,773,564.
Covista Inc. furnished an investor newsletter dated April 9, 2026, providing updates on key milestones, strategic developments, and operational progress. The newsletter is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.
The company emphasizes that the newsletter and related information under Regulation FD are furnished, not filed, so they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings. Covista also includes standard cautionary language that the newsletter contains forward-looking statements subject to risks described in its most recent Form 10-K and other SEC filings.
Covista Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0% beneficial ownership of Covista Inc common stock, with 0 shares beneficially owned. The filing describes an internal realignment of Vanguard and disaggregation of certain subsidiaries' holdings January 12, 2026.
The amendment is signed by Vanguard's Head of Global Fund Administration on 03/26/2026 and states that Vanguard and its managed accounts have the right to receive dividends or sale proceeds for reported positions; no other person holds more than 5%.
Covista Inc. lead independent director Michael W. Malafronte reported open-market purchases of a total of 36,036 shares of Covista common stock. The trades were executed on March 10 and 11 at weighted average prices around $100.9 per share.
One purchase of 11,841 shares on March 10 was held directly, leaving 113,205 directly held shares after that trade. Two additional purchases of 15,305 and 8,890 shares were made for the Michael W Malafronte 2016 Gift Trust, an irrevocable trust for which he serves as trustee, bringing that trust’s reported holdings to 25,395 shares after the March 11 transaction.
Covista Inc. lead independent director Michael W. Malafronte reported that the Michael W Malafronte 2016 Gift Trust bought 1,200 shares of common stock in an open-market purchase at a weighted average price of $97.97 per share. The trust now holds 1,200 shares indirectly, while Malafronte directly holds 101,364 shares after the reported transactions.
Covista Inc. entered into an Amendment No. 5 to its Credit Agreement on March 2, 2026, creating new 2026 Term Loans with an aggregate original principal of $510 million maturing on March 2, 2033. These loans bear interest at Term SOFR plus 2.25% (with a 0.75% SOFR floor) or an alternate base rate plus 1.25%, and the amendment reduced term loan interest margins by 0.50%.
The company used the 2026 Term Loan proceeds to fully refinance existing term loans under the prior credit agreement and to redeem in full its 5.50% Senior Secured Notes due 2028. The redemption covered approximately $404,950,000 of principal at 100% of par plus accrued interest, after which the related indenture was fully satisfied and discharged.
Covista Inc. is using its Investor Day to lay out a new three-year growth strategy, called Purpose at Scale, focused on expanding its healthcare education platform and addressing the U.S. healthcare workforce shortage. The company now serves more than 97,000 students and has graduated 24,000 healthcare professionals in the last year, including 10% of America's nurses. Covista is reaffirming its fiscal 2026 outlook and introducing long-term targets for fiscal 2027–2029, aiming for annual revenue growth of 6–8%, 7–10% and 8–11%, and adjusted earnings per share growth of 9–13%, 10–14% and 12–16%, respectively. Management also highlights disciplined capital allocation, potential M&A and share repurchases, and notes that its stock will begin trading under the new ticker CVSA on the NYSE.